CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AMGN

Etelcalcetide

Phase 3
Amgen Inc. (AMGN)
00%
What is LOA?

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q2 '27
AMGNPhase 3

Etelcalcetide Phase 3 Est. Readout

Etelcalcetide
Q2 2027~Q
CT.gov
00%
Competitive Landscape

1 competitor in Secondary Hyperparathyroidism

4151.TKRN1493
Phase 3
View Full Landscape
Drug Information

Target Indication

Secondary Hyperparathyroidism

Clinical Trial

NCT03299244

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book
Regulatory Approvals
EMA11/11/2016

Parsabiv

Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.

View on EMA
Drug Science
Mechanism of action & safety profile
Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ
Related Pipeline
Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Etanercept LiquidPhase 3

Rheumatoid Arthritis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.